The wide variety of presentations, which include polyarthritis, rashes, muscle weakness, pneumonitis, vasculitis and subcutaneous calcinosis, has resulted in fragmentation of responsibility for this condition between anumber of specialties and a large, widely scattered literature, mainly comprised of single case reports and small series. This, together with the relative rarity of polymyositis, is responsible for the paucity of large, rigorously analysed series of patients followed for a period appropriate to the natural history of this condition. An influential review by Bohan & Peter (1975) was rightly iconoclastic, tabulating conventional knowledge of the inflammatory myopathies under the headings of 'Fact, Fancy and Fiction', the length of the latter two sections attesting to the anecdotal basis of much of our current knowledge. They subsequently published a large (153 patients), computer-assisted analysis of a group of patients presenting to the University of California at Los Angeles (Bohan et al. 1977) . This study served as a basis for evaluation of their new and stricter diagnostic criteria, which are now gaining wide acceptance, and also for a revised classification (Pearson & Bohan 1977) .
Misdiagnosis and late diagnosis of polymyositis remain common. The 'classical' acute presentation, with rapidly progressive proximal muscular weakness associated with a heliotrope rash spreading from the eyelids to the rest of the face. and trunk, is readily recognized but occurs in only a minority of cases (De Vere & Bradley 1975) . Patients may present with polyarthritis, isolated skin involvement superficially resembling psoriasis, nailfold infarction or bleeding, malaise, vasculitis, subcutaneous or intramuscular cal-cinosis, and these features may precede clinical evidence of myopathy by months or even years. Each and even all of the three standard investigations for detecting muscle inflammation (muscle biopsy, electromyography and measurement of 'sarcoplasmic' serum enzyme levels) may be normal in the presence of active disease (De Vere & Bradley 1975) and none has specificity for polymyositis. Because of the lack of 'rule-in' and 'rule-out' tests and the absence of pathognomonic clinical features, Bohan & Peter (1975) proposed the assignation of confidence limits to their diagnostic criteria for polymyositis, and emphasized thorough investigation to exclude other muscular diseases of known cause or association, both at the time of presentation and at repeated intervals thereafter.
Muscle diseases which frequently cause diagnostic confusion with polymyositis are the various muscular dystrophies, hypothyroidism, osteomalacic myopathy, viral myositis and the druginduced inflammatory myopathies (Morgan- Hughes 1979) . Muscle biopsy remains the most specific diagnostic investigation though, because of the frequency of patchy muscle involvement, a normal biopsy does not exclude active disease. The application of needle biopsy to muscle (Young et al. 1978) facilitates examination of muscle from dilTerent sites and at repeated intervals, and may be the preferred method of obtaining biopsies in some patients. However, the small size of specimens obtained and the necessity for their precise orientation under the microscope accentuate the need for histopathological examination of muscle to be confined to centres with experience and interest in muscle disease.
The association of polymyositis with other socalled connective tissue diseases (systemic lupus erythematosus, scleroderma, rheumatoid arthritis, mixed connective tissue disease -but probably not polyarteritis: Pearson & Bohan 1977) and with neoplasia is well recognized. Because of selective bias resulting from reporting of individual cases and small series, literature reviews overestimate the frequency of these associations and the few large series provide more reliable estimates. The largest series concur in finding that fewer than 10%of patients with adult onset polymyositis had a possibly associated malignant condition, and that this was largely confined to patients over 50 (Pearson & Bohan 1977) . Though anecdotal accounts of interrelationships between muscle involvement and the associated malignancies abound, a large recent study found no difference between the presentation, clinical features and response to treatment of the muscle disease in these patients (Bohan et al. 1977) . It would appear to be more appropriate to regard polymyositis occurring in association with neoplasia or connective tissue disorder as an associated disease rather than a 'complication'. (If polymyositis is virally triggered, the association with these diseases might be through a secondary immune defect -as in the case of disseminated herpes virus infestations.)
Juvenile 'dermatomyositis' has been considered by some authorities to be a distinct disease entity (Banker & Victor 1966) . This view has been largely based on the clinically and histopathologically observed high frequency of vasculitis in children (Dubowitz 1978) . As vasculitis is not infrequent in adults with polymyositis (Whitaker & Engel 1972) , the case for regarding childhood-onset polymyositis as a separate disease appears tenuous. Nonetheless, polymyositis in children does have a different pattern of presentation and of complications, and requires specialized management, preferably in paediatric rheumatology centres. Vasculitis may belife-threatening, andjointcontractures and muscle atrophy permanently disabling. Subcutaneous calcinosis with associated skin ulceration is often distressing and may require long periods in hospital. Claims that anticalcinotic remedies are of any value are difficult to evaluate, as even large calcific deposits may gradually resolve on conventional treatment or possibly spontaneously (Sewell et al. 1978) .
The principles of management of polymyositis have not altered materially in the last 20 years. Studies demonstrating a steroid-sparing effect of such immunosuppressants as azathioprine (Bunch 1981) may have led to more widespread use of these in combination with steroids or as alternatives to steroids. First-line treatment of polymyositis still consists of systemic corticosteroids, initially in high dosage (usually over 60 mg prednisolone or equivalent per day). For those patients responding promptly to this treatment, policy for subsequent dose reduction and for maintenance remains controversial (Carpenter et al. 1977) .
The majority of those dying from polymyositis do so within the first year of presentation (Medsger et al. 1971) , and failure to respond to continued high-dose steroid therapy and early relapse occurring on maintenance therapy continue to carry a poor prognosis. [nvolvement of intercostal muscles often leads to severe pulmonary infection and carries a high mortality (Medsger et al. 1971) . Assisted ventilation should be considered early in patients with evidence of progressive ventilatory failure, and may need to be maintained for long periods. For those patients not responding to steroids, or relapsing on high doses of these, a variety of alternative treatments have been proposed, ranging' from cytotoxic agents (azathioprine, cyclophosphamide, methotrexate) to, recently, plasmapheresis (Dau 1981) and total body irradiation (King Engel et al. 1981) . While these last two treatments may prove effective in a proportion of recalcitrant cases, there are as yet insufficient data to establish their indications.
The hazards of continued high-dose steroid and immunosuppressant therapy are well recognized and may account for much of the late (5 years) mortality in polymyositis. Repeated titration of the dose ofsteroids or immunosuppressants against the patient's disease activity is vital but difficult. Serial muscle biopsies, sarcoplasmal enzyme estimations and quantitative electromyography have not proved to be reliable indicators of relapse and response, and repeated clinical assessments of muscle power, though crude, remain the most single important guide to management (Rose & Walton 1966 ). More precise measurements of muscle breakdown and of muscle inflammation would be of considerable clinical value. Serial nitrogen, phosphorus and methylhistidine urinary excretion values provide an indication of the rate of muscle breakdown (Edwards et al. 1979) but require the facilities of a metabolic unit and a precisely controlled diet. Measurement of muscle volumes at repeated intervals throughout treatment would also be valuable, and newer imaging techniques (ultrasound, CT scanning and nuclear magnetic resonance) will make this practicable. Measurements of contraction force of individual muscle groups are obviously relevant but, at present, are influenced by the degree of cooperation of the patient. Techniques have been developed to measure the force of isometric muscle contractions following graded electrical stimuli and these may prove of value in assessing different components of muscle action (Edwards et al. 1977) .
Research into the aetiology of polymyositis has largely concentrated on attempts to identify potentially myopathic viruses from affected patients at muscle biopsy and post-mortem (Chou 1973 , New England Journal of Medicine 1975 .
Actual isolations are few (coxsackie A, ECHO virus) and are of arguable relevance to polymyositis. There is an interesting possible analogy with postviral coxsackie B cardiomyopathy, where there is -increasing evidence that acute virus Infection can result in self-perpetuating myocardial disease possibly mediated by T-Iymphocytes (Wong et al. 1977) .
Interest in pathogenetic mechanisms in polymyositis has been stimulated by observations of lymphocyte-mediated myotoxicityin patients with active disease. A recently developed technique, employing tritium-labelled carnitine as a selective marker for myotubes in a 'target' monolayer culture from fetal musclecells (Cambridge& Stern 1981) , represents an interesting development of these studies which might eventually prove applicable to clinical monitoring. On present evidence, virus-triggered lymphocyte-mediated pathogenesis appears the most attractive hypothesis.
John R Sewell There is a traditional link between certain skin disorders and underlying internal malignancy. However, with the passage of time, many of these associations have been shown to be fortuitous, often being related to the patient's age rather than any specific predisposition (e.g. bullous pemphigoid). However, coeliac disease (CD) is associated with an increased risk of developing lymphomas and other malignancies. The bullous skin disease dermatitis herpetiformis (DH) is associated with an underlying gluten-sensitive 
